Home > Investors > Investor Updates > Investor Update
 

Investor Update
 
Basel, 29 April 2008

Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus

Dear Investor,
Genentech and Biogen Idec announced today top-line results from a phase II/III clinical study of Rituxan in Systemic Lupus Erythematosus. Roche has not opted in to this indication, however we wanted to make sure you are aware of this release.

View the press release
Deutsche Sprachversion     

English Version